Clinical Trials
158 trialsSACHI
Hutchmed
TroFuse-020
Merck Sharp & Dohme LLC
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
KANDLELIT-007
Merck Sharp & Dohme LLC
MK-2870-009
Merck Sharp & Dohme LLC
TroFuse-019
Merck Sharp & Dohme LLC
TROPION-Lung12
AstraZeneca
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
RELATIVITY1093
Bristol-Myers Squibb
SUNRAY-01
Eli Lilly and Company
SOHO-02
Bayer
MK-7339-012
Merck Sharp & Dohme LLC
INTerpath-009
Merck Sharp & Dohme LLC
TROPION-Lung15
AstraZeneca
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
MYSTIC
AstraZeneca
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Merck Sharp & Dohme LLC
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Krascendo 2
Hoffmann-La Roche
PAPILLON
Janssen Research & Development, LLC
MARIPOSA-2
Janssen Research & Development, LLC
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
REZILIENT4
Taiho Oncology, Inc.
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
NEPTUNE
AstraZeneca
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
IMbrella B
Hoffmann-La Roche
eVOLVE-Meso
AstraZeneca
AVANZAR
AstraZeneca
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
SAFFRON
AstraZeneca
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
AstraZeneca
POD1UM-304
Incyte Corporation
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Takeda
TROPION-Lung07
Daiichi Sankyo
Phase III Study of AK112 for NSCLC Patients
Summit Therapeutics
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Immutep S.A.S.
eVOLVE-Lung02
AstraZeneca
POSEIDON
AstraZeneca
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
mAbxience Research S.L.
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Clinical Study of AK112 for NSCLC Patients
Akeso
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
InxMed (Shanghai) Co., Ltd.
CANOPY-1
Novartis